United States: Sweeping Changes Proposed To Safe Harbors For Drug Discounts To Health Plans

The Department of Health and Human Services (HHS) has published a proposed rule that would make sweeping changes to the discount and rebate arrangements between drug manufacturers on the one hand and Medicare Part D plans and Medicaid managed care organizations (MCOs) (and pharmacy benefit managers (PBMs) on the behalf of such plans or organizations) on the other.1 The intent of the proposed rule is to exclude from regulatory safe harbor protection such discounts and rebates and replace them with discounts provided directly to federal health care program beneficiaries.

HHS has said it believes the amount of such point-of-sale discounts would be greater than the likely increased Part D premiums that beneficiaries would face due to the loss of rebates by PBMs and Plan D sponsors. It is not clear, however, whether the proposed rule would have the full effect intended by HHS; the statutory discount exception to the federal Anti-Kickback Statute (AKS) would still be available to drugmakers, and throughout the explanation to the proposed rule, HHS expressed uncertainty about its scope and actual impact. Nevertheless, HHS' interpretation of the current discount safe harbor (as reflected in the preamble accompanying the proposed rule) and the changes in the proposed rule are significant given that discount and rebate arrangements with Part D plans, Medicaid MCOs and PBMs acting on their behalf may run afoul of the AKS if they fall outside the regulatory safe harbor and statutory discount exception. Drugmakers and other industry participants should carefully assess their existing discount and rebate arrangements in light of both HHS' views of the current safe harbor and the proposed rule. 

Current Statutory and Regulatory Framework

Discounts and certain other price reductions offered by prescription drug manufacturers are not considered prohibited remuneration under the AKS if they are structured to comply with either the statutory discount exception to the statute (42 U.S.C. § 1320a-7b(b)(3)(A)) or the regulatory discount safe harbor promulgated by the HHS Office of Inspector General (HHS OIG). HHS' new proposal would exclude from the regulatory safe harbor discounts and rebates paid to Medicare Part D plans, Medicaid MCOs and PBMs acting on their behalf. Importantly, HHS' proposed rule would not alter the regulatory safe harbor protection for drug discount arrangements with other entities (e.g., wholesalers). And HHS' regulatory action would not change the statutory exception protecting certain discounts in 42 U.S.C. § 1320a-7b(b)(3)(A).

HHS Proposal

The proposed rule has two basic components. First, it would exclude certain drug discounts and rebates from safe harbor protection. Second, and in lieu of such exclusion, it would create new safe harbors for discounts offered at the point of sale and for bona fide service fees paid by drug manufacturers to PBMs.2

Safe Harbor Exclusion for Discounts and Rebates to Part D Plans, Medicaid MCOs and PBMs Acting on Their Behalf

HHS has stated that the proposed rule is intended to exclude from the current discount safe harbor any price reductions (whether in the form of upfront discounts or later-reconciled rebates) from drug manufacturers to Medicare Part D plans or Medicaid MCOs, either directly or through PBMs acting under contract with such plans or organizations, in connection with the sale or purchase of prescription pharmaceutical products, unless such reduction is required by law. As drafted, the proposed rule does not apply to discounts and rebates on pharmaceutical products under other HHS programs (e.g., Medicare Part B), but HHS is soliciting comments on whether it should do so.3

While the proposed rule is limited to discounts under these HHS programs, the preamble includes a reminder of the HHS OIG's long-standing concern about "carve out" arrangements that exclude federal programs from discount arrangements offered to private plans. To this end, HHS emphasizes that the proposed rule would not alter the discount safe harbor's exclusion for price reductions offered to one payer but not to Medicare or Medicaid, particularly when such discounts serve as inducements for the purchase of federally reimbursable products. HHS provides an example of an arrangement that would trigger such concern: a discount on a product to an insurer for its private pay plans conditioned (explicitly or implicitly) on the product's favorable formulary placement across all its plans (including Part D plans). HHS states that such an arrangement would involve prohibited remuneration that would implicate the AKS and not be protected under the current or proposed changes to the discount safe harbor.

The proposed rule would create new definitions for purposes of the discount safe harbor for the terms "manufacturer," "wholesaler," "distributor," "pharmacy benefit manager" and "prescription pharmaceutical product." This would be the first time such terms are incorporated into and defined in the discount safe harbor — an astonishing fact given that the discount safe harbor was established in 1991 and has been modified several times in the ensuing years.

New Safe Harbor for Point-of-Sale Discounts

In lieu of discounts to plan sponsors and PBMs, HHS is proposing a new safe harbor for point-of-sale price reductions that meet certain criteria. To qualify for such protection, three criteria must be met.

  1. The price reduction must be set in advance, which is defined to mean fixed and disclosed in writing by the time of initial purchase by the beneficiary.
  2. The price reduction may not involve a rebate (other than if required by law) unless the full value of the reduction in price is provided to the dispensing pharmacy through a chargeback. (Of note, HHS believes the current rebate frameworks under which manufacturers pay Part D plans and Medicaid MCOs — including through PBMs — would not meet this criteria unless the dispensing pharmacy receives the full value of the reduction in price.)
  3. The reduction in price must be completely reflected in the price the pharmacy charges to the beneficiary at the point of sale. Under these criteria, HHS intends to exclude from protection arrangements that mimic rebates but are described in other ways in the underlying contracts (e.g., fees that are on a percentage of a pharmaceutical product's list price). HHS states that it intends for the point-of-sale safe harbor to protect price reductions regardless of the portion of cost the beneficiary is responsible for, and it requests comment on how it would apply during periods of 100 percent beneficiary cost-sharing.

New Safe Harbor for PBM Service Fees

The final component of the proposed rule is a new discount safe harbor provision for certain fixed fees paid by drug manufacturers to PBMs. To be protected under the new safe harbor, the arrangement would need to be pursuant to a written agreement that covers all services the PBM provides to the manufacturer for the term of the arrangement and specifies the services to be provided and the compensation associated with such services. In addition, the compensation paid to the PBM must be consistent with fair market value, fixed in amount (i.e., not based on a percentage of sales) and not determined in a manner that takes into account the volume or value of any business between the parties. To be eligible for the safe harbor, PBMs must disclose in writing to each health plan, at least annually, the services the PBM provides to each manufacturer (and disclose the same to HHS upon request). HHS says the proposed PBM service fee safe harbor is not intended to curtail or discourage "value-based" contracting arrangements and invites comment on whether the proposed safe harbor would, in fact, stifle innovative and nonabusive value-based arrangements.

Implications for Drug Manufacturers, PBMs and Drug Plan Sponsors

HHS' proposed rule and comments in the preamble thereto pose significant compliance challenges for drug manufacturers, Part D plans, Medicaid MCOs and PBMs acting on their behalf. In particular, the preamble suggests that HHS believes some existing drug discounting and rebate arrangements between and among these entities may not be lawful, and goes on to say that such arrangements will be excluded from safe harbor protection in the future.

With respect to the proposed rule, HHS recognizes the inherent complexity of its proposed changes and is soliciting comments on whether they would accomplish HHS' objectives. Nevertheless, the department proposes that the rule take effect on January 1,2020 — a mere 11 months from now, and notwithstanding the fact that HHS may make further changes before the rule is finalized. Perhaps to encourage industry participants to move more quickly to provide point-of-sale discounts, HHS also proposes that the new point-of-sale safe harbor take effect 60 days after the rule is finalized. Given the long lead time for drugmakers to negotiate discount and rebate agreements, HHS should provide a much longer effective date for the proposed safe harbor exclusions (e.g., a minimum of 12 to 18 months from when the rule is finalized). Industry participants should emphasize the need for a longer phase-in schedule when commenting on the proposed rule.

In the meantime, companies involved in arrangements covered by the proposed rule should consider taking a number of practical compliance steps in the near future.4

First, companies should review their current contracts and arrangements in light of HHS' commentary that certain price reductions from drug manufacturers to Plan D sponsors and Medicaid MCOs (and PBMs acting on their behalf) may not qualify for protection under the existing discount safe harbor. For example, the preamble to the proposed rule states that where arrangements provide a discount to private health plans for formulary placement that applies (explicitly or implicitly) to both private and federal health program plans, the discounts constitute prohibited remuneration under the AKS. Equally importantly, HHS also suggests that retrospective rebate arrangements may not qualify for protection under the discount safe harbors. Even if these interpretations prove to be wrong, efforts to review contractual arrangements will help to identify those that might need to be modified if the rule is finalized.

Second, companies should begin assessing the business opportunities and legal and compliance risks associated with point-of-sale discounts and PBM service fee arrangements. In particular, pharmaceutical companies should review their contractual arrangements with PBMs to identify any revisions that might be necessary to comply with the proposed rule, if finalized.

Finally, companies should consider the legal and compliance implications — whether intended by HHS or not — in other areas, such as government price reporting requirements and how the proposed rule might impact such activities (from both a business and legal perspective).

Footnotes

1 The text of the proposed rule would remove safe harbor protection for certain price reductions to "a plan sponsor under Medicare Part D, a Medicaid Managed Care Organization as defined in section 1903(m) of the Act, or to a pharmacy benefit manager acting under contract with a plan sponsor under Medicare Part D, or Medicaid Managed Care Organization." For brevity, these entities are referred to herein as "Part D plans, Medicaid MCOs and PBMs acting on their behalf." See the appendix for the proposed changes.

2 The preamble to the proposed rule includes a useful history of the establishment and subsequent modifications to the discount safe harbor, and the HHS OIG's evolving interpretation of the safe harbor's provisions. See Proposed Rule (pp. 29-34).

3 Interestingly, while the proposed rule calls for removal of safe harbor protection for drug discounts and rebates to Part D plans and Medicaid MCOs, a footnote in the preamble questions whether such arrangements are even protected under the existing discount safe harbor:

We recognize that the payments manufacturers retrospectively make to PBMs under rebate arrangements would not constitute discounts or other reductions in price to the extent such payments are retained by the PBM and not passed through to any buyer. We do not intent to imply through the issuance of this proposed rule that such payments qualify for safe harbor protection under 42 CFR § 1001.952(h).

4 A nonexhaustive list of HHS OIG advisory opinions interpreting the safe harbor discount in the context of pharmaceuticals and related products include: Adv. Op. 14-05 (concerning a pharmaceutical manufacturer's direct-to-patient product sales program that allows eligible patients to purchase one of the manufacturer's brand-name products for a fixed cash price from an online retail pharmacy vendor outside of any applicable prescription drug insurance benefit); Adv. Op. 13-07 ( concerning a tiered rebate program in which the rebate tiers would be reached based on the combination of purchases of both federally reimbursable products and nonfederally reimbursable products); Adv. Op. 98-2 (concerning certain pharmaceutical discount pricing arrangements that are limited to arrangements between a manufacturer and wholesaler); and Adv. Op. 02-10 (concerning the offering of discounts to customers, based on their purchases of dialysis equipment and supplies).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions